Skip to primary navigation
Skip to main content
Skip to footer

Neurotech International

ASX:NTI

Home
Corporate
Development Programs
Investors
Contact

Neurotech’s NTI164 shows excellent tolerability in key preclinical toxicology studies

6 May 2025 News & Media

Read the full article here.

Footer

Suite 102 / Level 1, 55 Collins Street
Melbourne VIC 3000
Australia

moc.l1775567713anoit1775567713anret1775567713nihce1775567713torue1775567713n@ofn1775567713i1775567713

+61 (3) 9498 3132

Subscribe to our latest announcements

"*" indicates required fields

Name*

First Last

Email*

Email

This field is for validation purposes and should be left unchanged.

Copyright © 2026 Neurotech International • Site by White Noise Communications

Download prospectus